Clinical Trial Update: BKM120 as Second-line Therapy for Advanced Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for BKM120 as second-line therapy in advanced endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• BKM120 (Buparlisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-04-10